tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
PremiumRatingsDenali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside
29d ago
Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
Premium
Ratings
Denali Therapeutics: Strengthening LSD Clinical Profile and Attractive Risk‑Reward Support Buy Rating
1M ago
Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing
Premium
Company Announcements
Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing
2M ago
Denali Therapeutics announces publication of Phase 1/2 study of DNL310
PremiumThe FlyDenali Therapeutics announces publication of Phase 1/2 study of DNL310
2M ago
Denali Therapeutics price target lowered to $30 from $31 at Wedbush
Premium
The Fly
Denali Therapeutics price target lowered to $30 from $31 at Wedbush
3M ago
Denali Therapeutics Announces $200M Public Offering
Premium
Company Announcements
Denali Therapeutics Announces $200M Public Offering
3M ago
Denali Therapeutics price target raised to $29 from $26 at BofA
PremiumThe FlyDenali Therapeutics price target raised to $29 from $26 at BofA
3M ago
Denali Therapeutics price target raised to $31 from $30 at Wedbush
Premium
The Fly
Denali Therapeutics price target raised to $31 from $30 at Wedbush
3M ago
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
Premium
Ratings
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100